Ocugen (OCGN) Competitors $1.02 +0.02 (+2.00%) Closing price 04:00 PM EasternExtended Trading$1.01 -0.01 (-0.49%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCGN vs. MRNA, PFE, WVE, AMPH, GPCR, COGT, NTLA, ARDX, AUPH, and VERVShould you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include Moderna (MRNA), Pfizer (PFE), WAVE Life Sciences (WVE), Amphastar Pharmaceuticals (AMPH), Structure Therapeutics (GPCR), Cogent Biosciences (COGT), Intellia Therapeutics (NTLA), Ardelyx (ARDX), Aurinia Pharmaceuticals (AUPH), and Verve Therapeutics (VERV). These companies are all part of the "medical" sector. Ocugen vs. Its Competitors Moderna Pfizer WAVE Life Sciences Amphastar Pharmaceuticals Structure Therapeutics Cogent Biosciences Intellia Therapeutics Ardelyx Aurinia Pharmaceuticals Verve Therapeutics Ocugen (NASDAQ:OCGN) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation. Which has stronger valuation & earnings, OCGN or MRNA? Ocugen has higher earnings, but lower revenue than Moderna. Ocugen is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcugen$4.05M73.55-$54.05M-$0.19-5.37Moderna$3.24B3.74-$3.56B-$8.73-3.58 Do analysts prefer OCGN or MRNA? Ocugen presently has a consensus price target of $6.00, indicating a potential upside of 488.24%. Moderna has a consensus price target of $46.61, indicating a potential upside of 49.11%. Given Ocugen's stronger consensus rating and higher possible upside, equities analysts plainly believe Ocugen is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Moderna 4 Sell rating(s) 17 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Do insiders and institutionals have more ownership in OCGN or MRNA? 10.3% of Ocugen shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 4.4% of Ocugen shares are owned by insiders. Comparatively, 11.0% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, OCGN or MRNA? Ocugen has a beta of 4.18, indicating that its share price is 318% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Is OCGN or MRNA more profitable? Moderna has a net margin of -105.67% compared to Ocugen's net margin of -1,271.12%. Moderna's return on equity of -28.69% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Ocugen-1,271.12% -223.00% -92.20% Moderna -105.67%-28.69%-21.94% Does the media prefer OCGN or MRNA? In the previous week, Moderna had 15 more articles in the media than Ocugen. MarketBeat recorded 21 mentions for Moderna and 6 mentions for Ocugen. Ocugen's average media sentiment score of 0.85 beat Moderna's score of 0.59 indicating that Ocugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 7 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive SummaryModerna beats Ocugen on 9 of the 16 factors compared between the two stocks. Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCGN vs. The Competition Export to ExcelMetricOcugenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$292.03M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio-5.378.2821.0120.09Price / Sales73.55303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book10.207.678.125.65Net Income-$54.05M-$55.28M$3.25B$257.91M7 Day Performance-10.53%2.50%0.97%2.09%1 Month Performance-6.42%11.70%7.36%11.13%1 Year Performance-37.61%4.89%31.31%18.40% Ocugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCGNOcugen1.2758 of 5 stars$1.02+2.0%$6.00+488.2%-45.4%$292.03M$4.05M-5.3780News CoverageMRNAModerna4.2835 of 5 stars$29.90-1.9%$46.61+55.9%-74.0%$11.56B$3.24B-3.425,800Trending NewsOptions VolumeAnalyst RevisionPFEPfizer4.9618 of 5 stars$25.23-0.6%$28.55+13.2%-18.1%$143.44B$63.63B18.2881,000Trending NewsWVEWAVE Life Sciences4.5817 of 5 stars$7.06+1.6%$20.50+190.4%+35.5%$1.10B$108.30M-8.40240Analyst ForecastAMPHAmphastar Pharmaceuticals4.3171 of 5 stars$22.86-1.5%$32.33+41.4%-45.0%$1.08B$731.97M8.282,028GPCRStructure Therapeutics2.9436 of 5 stars$18.73-8.1%$76.17+306.7%-49.1%$1.07BN/A-21.53136COGTCogent Biosciences3.5461 of 5 stars$9.35+23.4%$16.33+74.7%+35.9%$1.06BN/A-5.0880Trending NewsAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeNTLAIntellia Therapeutics4.4128 of 5 stars$10.25-4.6%$33.37+225.5%-56.8%$1.06B$57.88M-1.96600Gap UpARDXArdelyx4.1637 of 5 stars$4.35+1.9%$10.89+150.3%-21.4%$1.04B$333.61M-19.7790Analyst RevisionAUPHAurinia Pharmaceuticals3.2887 of 5 stars$7.47-1.6%$11.50+53.9%+55.3%$1.01B$235.13M26.68300Positive NewsVERVVerve Therapeutics2.8995 of 5 stars$11.16-1.1%$14.57+30.6%+45.8%$994.80M$32.33M-5.29110 Related Companies and Tools Related Companies Moderna Alternatives Pfizer Alternatives WAVE Life Sciences Alternatives Amphastar Pharmaceuticals Alternatives Structure Therapeutics Alternatives Cogent Biosciences Alternatives Intellia Therapeutics Alternatives Ardelyx Alternatives Aurinia Pharmaceuticals Alternatives Verve Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCGN) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
